Full Text View
Tabular View
No Study Results Posted
Related Studies
Estrogen Modulation of Mood and Cognition Following Monoaminergic Depletion in Post-Menopausal Women
This study is currently recruiting participants.
Verified by National Center for Research Resources (NCRR), December 2003
First Received: June 1, 2000   Last Updated: June 23, 2005   History of Changes
Sponsored by: National Center for Research Resources (NCRR)
Information provided by: National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier: NCT00005768
  Purpose

This study will examine whether estrogen administration in postmenopausal women can alter the response to changes in brain chemistry brought about by dietary manipulation. Women who are recently menopausal (50-60 yrs. of age) and over 20 years postmenopausal (>70 yrs. of age) will take estrogen or placebo for three months. At the end of that time they will participate in three challenges using dietary techniques to briefly change the relative amounts of neurotransmitters in the brain that are believed to be related to mood regulation (serotonin, dopamine, and norepinephrine). Previous research has shown that these dietary manipulations can briefly produce negative changes in mood. The investigator hypothesizes that estrogen administration will blunt or buffer these negative effects in a quantifiable way. The investigator believes that this will provide a direct test of the ability of estrogen to meaningfully change the brain chemistry of mood in a clinically measurable and positive way. The proposed procedure will also allow assessment of the effects of estrogen on brain neurotransmitter systems after many years of very low estrogen levels.


Condition Intervention Phase
Menopause
Drug: Estrogen
Phase II

MedlinePlus related topics: Menopause
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind
  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Postmenopausal
  • Non-smoker
  • BMI <30
  • Healthy
  • Without surgically-induced menopause
  • Not on HRT or >1 year post HRT
  • Normal mammogram within last year
  • No cardiovascular disease other than mild hypertension
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005768

Contacts
Contact: Julie Dumas 1-802-847-2523

Locations
United States, Vermont
University of Vermont Recruiting
Burlington, Vermont, United States, 05401
Contact: Julie Dumas     802-847-2523        
Principal Investigator: Paul Newhouse, M.D.            
Sponsors and Collaborators
  More Information

No publications provided

Study ID Numbers: NCRR-M01RR00109-0741, M01RR00109
Study First Received: June 1, 2000
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00005768     History of Changes
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Estrogens
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Hormones
Menopause

Additional relevant MeSH terms:
Estrogens
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Hormones
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 07, 2009